HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date: Tuesday, September 6, 2022Time: 1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator: Eric Joseph, Ph.D.HilleVax Participant: Robert Hershberg, M.D., Ph.D.,
